Group 1 - Anbotong plans to issue H-shares and list on the Hong Kong Stock Exchange, with the board authorizing management to start preparations within 12 months [1] - Xiangsheng Medical proposes a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [2] - Junshi Biosciences receives FDA approval for clinical trials of JS212, a dual-specific antibody-drug conjugate for treating advanced solid tumors [3] Group 2 - Zhonghuan Environmental plans to raise up to 300 million yuan by issuing shares to a specific entity, with funds allocated for working capital and bank loan repayment [4] - Guao Technology announces a change in actual control to Xu Yinghui, with stock resuming trading on December 15 [5] - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol project in Heilongjiang [6] Group 3 - Shanghai Airport reports a 15.47% year-on-year increase in passenger throughput at Pudong International Airport for November [7] - Innovent Biologics achieves primary endpoint in a Phase IIb study of Obinutuzumab for systemic lupus erythematosus, with plans for a Phase III trial [8] - Saiyi Information leads a national major science and technology project on intelligent manufacturing systems and robotics [9] Group 4 - Yipin Hong's Qinxing Qingjie oral solution is approved as a national second-level protected traditional Chinese medicine [10] - Yipin Hong's stake in US-based Arthrosi Therapeutics is set to be acquired by Sobi for a total of up to 950 million USD [11] - Pudong Jinqiao announces the resignation of Chairman Wang Ying due to job transfer [12] Group 5 - Jiaze New Energy plans to invest in two wind power projects with a total estimated investment of approximately 2.366 billion yuan [13] - Jinpan Technology receives approval from the CSRC for issuing convertible bonds to unspecified investors [14] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for 356 million yuan [15] Group 6 - Jiuan Medical's US subsidiary receives pre-market notification from the FDA for multiple testing products [16][17] - Changfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [18] - Chenfeng Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [19][20][21][22]

新京报贝壳财经讯 12月14日，祥生医疗发布公告称，2025年前三季度公司拟向全体股东每10股派发现 金红利3元（含税），合计拟派发现金红利3356.24万元（含税），本次利润分配不进行资本公积转增股 本，不送红股，尚需提交公司2025年第三次临时股东会审议通过后方可实施。 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-048 无锡祥生医疗科技股份有限公司 关于变更公司注册资本、修订《公司章程》 并办理工商变更登记的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于2025年12月12日召开第三届董事会第十七次会 议，审议通过了《关于变更公司注册资本、修订〈公司章程〉并办理工商变更登记的议案》。具体情况 如下： 一、公司注册资本变更相关情况 根据公司2025年第二次临时股东会授权，公司于2025年10月23日召开了第三届董事会第十六次会议、第 三届董事会薪酬与考核委员会第六次会议，审议通过了《关于向2025年限制性股票激励计划激励对象授 予限制性股票的议案》，确定2025年10月23日为授予日，以16.50元/股的授予价格向17名激励对象授予 160,000股限制性股票。具体内容参见公司于2025年10月24日刊登于上海证券交易所网站 （www.sse.com.cn）的《无锡祥生医疗科技股份有限公司关于向2025年限制性股票 ...

证券日报网讯 12月14日晚间，祥生医疗发布公告称，公司已于2025年12月10日在中国证券登记结算有 限公司上海分公司办理完成2025年限制性股票激励计划的股票授予登记工作，股本总数由112124537股 增至112125613股，注册资本相应由112124537.00元增至112125613.00元，并据此修订《公司章程》注册 资本及股份总数条款，办理工商变更登记。 （编辑 王江浩） ...

（编辑 王江浩） 证券日报网讯 12月14日晚间，祥生医疗发布公告称，2025年前三季度公司拟向全体股东每10股派发现 金红利3元（含税），合计拟派发现金红利33，562，425.90元（含税），本次利润分配不进行资本公积 转增股本，不送红股，尚需提交公司2025年第三次临时股东会审议通过后方可实施。 ...

Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution plan for the first three quarters, proposing a cash dividend of 3 yuan per 10 shares to all shareholders, which reflects the company's commitment to returning value to its investors [1] Financial Performance - As of September 30, 2025, the total share capital of the company is 112,124,537 shares, with a base for the dividend calculation of 111,874,753 shares after deducting 249,784 shares held in the company's repurchase account [1] - The total cash dividend to be distributed amounts to 33.5624 million yuan (including tax), representing 35.73% of the net profit attributable to shareholders of the listed company as reported in the Q3 2025 consolidated financial statements [1] Business Overview - Xiangsheng Medical specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment, having developed a comprehensive set of core technologies in ultrasound imaging, including 2D, 3D, and 4D ultrasound, as well as AI cloud platform solutions [1] - In the first three quarters of this year, the company achieved an operating income of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.9205 million yuan, a year-on-year decrease of 4.56% [1]

Corporate Changes - Wang Ying, the chairman of Pudong Jinqiao, has resigned due to work transfer [2] - Xu Yinghui has become the new actual controller of Gu Ao Technology after a voting rights entrustment agreement [4][5] Profit Distribution - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [3] Investment Projects - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol co-production project in Jixi City, Heilongjiang Province [6] - Longfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [11] Financing Activities - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [7] Acquisitions - Zoli Pharmaceutical has signed an agreement to acquire a multi-trace element injection asset group from Future Medicine for a total price of 356 million yuan [8] Product Approvals - Nine安 Medical's U.S. subsidiary has received pre-market notifications from the FDA for its multi-detection kits for various viruses [9] National Projects - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [10]

祥生医疗表示，结合目前公司募集资金投资项目的实际建设情况和投资进度，在募集资金投资用途及投 资规模不发生变更的情况下，对研发创新及营销运营基地建设项目、创新与发展储备资金两个项目达到 预定可使用状态日期进行调整，原计划项目达到预定可使用状态日期为2025年12月31日。调整后，项目 达到预定可使用状态日期为2026年12月31日。 北京商报讯(记者丁宁)12月14日晚间，祥生医疗(688358)发布公告称，公司于12月12日召开第三届董事 会第十七次会议，审议通过了公司《关于部分募投项目延期的议案》，同意公司对部分募投项目达到预 定可使用状态的时间进行延期。 ...

Group 1 - Pudong Jinqiao's chairman Wang Ying has resigned due to job transfer, ceasing to hold positions as director, chairman, and committee member [2] - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares to all shareholders based on the total share capital [3] - Gu Ao Technology's actual controller has changed to Xu Yinghui, with stock resuming trading on December 15 [4] Group 2 - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City [5] - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [6] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [7] Group 3 - Jiuan Medical's U.S. subsidiary has received pre-market notifications from the FDA for four and three-in-one testing products [8] - Saiyi Information has been approved for a national major science and technology project focusing on intelligent manufacturing systems and robotics [9] - Changfei Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [10] Group 4 - Chengfeng Technology's shareholder, Hangzhou Hongwo, plans to reduce its stake by up to 3% of the company's shares [12] - Minxin Co., Ltd.'s deputy general manager plans to reduce holdings by up to 220,000 shares, representing 0.3925% of the total share capital [13] - Xinle Energy's director plans to reduce holdings by up to 400,000 shares, accounting for 0.07% of the total share capital [14]

北京商报讯（记者 丁宁）12月14日晚间，祥生医疗（688358）发布2025年前三季度利润分配方案显 示，公司拟向全体股东每10股派发现金红利3元（含税）。 公告显示，此次分红合计拟派发现金红利3356.24万元（含税），本次公司现金分红金额占公司2025年 三季度报告合并报表归属净利润的比例为35.73%。 ...